Development of glycoprotein IIb–IIIa antagonists: translation of pharmacodynamic effects into clinical benefit

This article will review the development of glycoprotein IIb-IIIa antagonists, with particular emphasis on the characteristics and pharmacodynamic studies of each agent that is available for clinical use. Abciximab is a Fab fragment of the 7E3 antibody that has high affinity and a slow rate of disso... View More